ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tapinarof

Also written as “Tapinarof cream, 1%”, “tapinarof cream, 1%” and “WBI-1001”.

Its studies are mostly in Psoriasis · Dermatitis, Atopic · Skin Diseases, led by 5 companies.

Drug pageTapinarof: every studyMany companies study it; this page follows only the 25 they lead. All 34 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 26, 202225 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organonits history only121 open or runningphase 4since Dec 26, 2022May 16, 2019Aug 2027phase 3 · NCT07265479
GlaxoSmithKline80 open or runningphase 3since Jun 27, 2017Oct 31, 2013none ahead
Welichem Biotechits history only30 open or runningphase 2since Feb 3, 2009Feb 3, 2009none ahead
Sun Pharmaceutical Industriesits history only10 open or runningphase 1since Apr 15, 2026Apr 15, 2026none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 3since Dec 16, 2024Dec 16, 2024none ahead

Also a collaborator on its studies: Teva Pharmaceuticals, IQVIA Biotech, PPD DEVELOPMENT, LP, Q2 Solutions and iCardiac Technologies.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 31, 2013First study: phase 1 study in PsoriasisFirst studyNCT01984775 · 52 enrolled · United States, Germany
  2. Mar 6, 2015Phase 1 study in Dermatitis, AtopicNCT02411162 · 15 enrolled · United States
  3. May 21, 2015Phase 1 study in Dermatitis, AtopicNCT02466152 · 11 enrolled · Canada
  4. Sep 17, 2015Phase 1 study in Dermatitis, AtopicNCT02637206 · 26 enrolled · Japan
  5. Sep 28, 20152 phase 2 studiesNCT02564055, NCT02564042
  6. Dec 9, 2016Named tapinarofINNProposed as its International Nonproprietary Name in WHO's List 116 · before, WBI-1001
  7. Jun 27, 2017Phase 3 study in PsoriasisNCT03202004
  8. Jun 27, 2017Phase 1 study in PsoriasisNCT03201978

TargetBeta

AHR →read by rule
“Aryl hydrocarbon receptor agonist”ChEMBL 37, by rule

Studies

All 8 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03202004Psoriasis3WithdrawnSep 28, 20180
NCT03201978Psoriasis1WithdrawnMay 15, 20180
NCT02564055Dermatitis, Atopic · United States, Canada, Japan2CompletedJan 1, 2017247
NCT02564042Psoriasis · United States, Canada, Japan2CompletedOct 1, 2016227
NCT02637206Dermatitis, Atopic · Japan1CompletedDec 2, 201526
NCT02466152Dermatitis, Atopic · Canada1CompletedOct 27, 201511
NCT02411162Dermatitis, Atopic · United States1CompletedSep 24, 201515
NCT01984775Psoriasis · United States, Germany1CompletedJul 2, 201452

How it is read

Names in the registry

  • “Tapinarof cream, 1%”, 4 entries
  • “tapinarof cream, 1%”, 4 entries
  • “WBI-1001”, 3 entries
  • “Tapinarof”, 2 entries
  • “GSK2894512 1% Cream”, 2 entries

Codes read as this program: GSK2894512.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.